Romain Daillere

Romain Daillere

Company: EverImmune

Job title: Head of Preclinical Research & Co-founder


ONCOBAX®-AK, a game-changer Live Biotherapeutic Product for anticancer immunotherapy 5:30 pm

The composition of the gut microbiota influences the effectiveness of anticancer immunotherapy EverImmune has developed Oncobax®-AK, a breakthrough microbiome technology as oral adjuvant for anticancer immunotherapy in NSCLC and RCC patients treated with ICIs, that will enter into clinics 2nd quarter 2022. EverImmune has developed companion diagnosis tools to identify patients amenable to Oncobax®-AKRead more

day: Day One – Track B – 3

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.